Fulcrum Therapeutics, Inc. announced that Esther Rajavelu has resigned from her position as chief financial officer, effective April 21, 2023. Ms. Rajavelu will serve in a consulting role to ensure the continuity of the company's financial operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.45 USD | -4.49% | -10.13% | +10.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.37% | 463M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Announces Resignation of Esther Rajavelu as Chief Financial Officer, Effective April 21, 2023